Chimerix to Present at Upcoming Investor Conferences
November 04 2019 - 4:01PM
Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company focused
on accelerating the development of medicines to treat cancer and
other serious diseases, today announced that management will
present at two upcoming investor conferences in November.
- Credit Suisse 28th Annual Healthcare
Conference on Wednesday, November 13 at 11:30 a.m. MT in
Scottsdale, AZ
- Jefferies 2019 London Healthcare Conference on
Wednesday, November 20 at 6:00 p.m. GMT in London, UK
A live audio webcast of each presentation will be available on
the Investor Relations section of Chimerix’s website at
ir.chimerix.com, where they will be archived for approximately 90
days.
About Chimerix
Chimerix is a development-stage biopharmaceutical company
dedicated to accelerating the advancement of innovative medicines
that make a meaningful impact in the lives of patients living with
cancer and other serious diseases. The two clinical-stage
development programs are dociparstat sodium (DSTAT) and
brincidofovir (BCV).
Dociparstat sodium is a potential first-in-class
glycosaminoglycan biologic derived from porcine heparin that has
low anticoagulant activity but retains the ability to inhibit
activities of several key proteins implicated in the retention and
viability of AML blasts and leukemic stem cells in the bone marrow
during chemotherapy (e.g., CXCL12, selectins, HMGB1).
Mobilization of AML blasts and leukemic stem cells from the bone
marrow has been associated with enhanced chemosensitivity and may
be a primary mechanism accounting for the observed increases in EFS
and OS in Phase 2 with DSTAT versus placebo. Randomized Phase 2
data suggest that DSTAT may also accelerate platelet recovery
post-chemotherapy via inhibition of platelet factor 4, a negative
regulator of platelet production that impairs platelet recovery
following chemotherapy. BCV is a lipid conjugate DNA polymerase
inhibitor in development as a medical countermeasure for
smallpox. For further information, please visit the Chimerix
website, www.chimerix.com.
CONTACT:
Investor Relations: Michelle LaSpaluto
919-972-7115ir@chimerix.com
Will O’ConnorStern Investor
Relations212-362-1200will@sternir.com
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Chimerix (NASDAQ:CMRX)
Historical Stock Chart
From Apr 2023 to Apr 2024